Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-010391 Tablets in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT07624214 is registered in ClinicalTrials.gov with Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. as lead sponsor.

NCT NCT07624214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-010391 Tablets in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Lead sponsor
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
April 30, 2029
Enrollment
198 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal cancer (crc), non-small cell lung cancer (nsclc), pancreatic ductal adenocarcinoma (pdac)